Ignite Creation Date:
2026-03-26 @ 3:19 PM
Ignite Modification Date:
2026-03-31 @ 5:16 AM
Study NCT ID:
NCT07314060
Status:
RECRUITING
Last Update Posted:
2026-03-24
First Post:
2025-12-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2026-03-25'}, 'conditionBrowseModule': {'meshes': [{'id': 'D011565', 'term': 'Psoriasis'}], 'ancestors': [{'id': 'D017444', 'term': 'Skin Diseases, Papulosquamous'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 36}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2026-03-19', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-10', 'completionDateStruct': {'date': '2027-07', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2026-03-20', 'studyFirstSubmitDate': '2025-12-15', 'studyFirstSubmitQcDate': '2025-12-31', 'lastUpdatePostDateStruct': {'date': '2026-03-24', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2026-01-02', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-12', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of patients with a score of 0 for the pustule subterm', 'timeFrame': '1 week', 'description': "Percentage of patients with a Physician's Global Assessment of Generalized Pustular Psoriasis (GPPGA) pustular subitem of 0 (no visible pustules) at week 1 among all enrolled patients."}], 'secondaryOutcomes': [{'measure': 'Percentage of patients with a Generalized Pustular Psoriasis Physician Global Assessment(GPPGA) total score of 0 or 1', 'timeFrame': '1 week and 4 weeks', 'description': 'Percentage of patients with a total Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score of 0 (clear) or 1 (almost clear) at weeks 1 and 4.'}, {'measure': 'Percentage change from baseline in Generalized Pustular Psoriasis Area and Severity Index (GPPASI) total score', 'timeFrame': '1 week and 4 weeks', 'description': 'Percentage change from baseline in the total score of generalized pustular psoriasis area and severity index (GPPASI) at week 1 and week 4.'}, {'measure': 'Change from baseline in Generalized Pustular Psoriasis Area and Severity Index(GPPASI) total score', 'timeFrame': '1 week and 4 weeks', 'description': 'Change from baseline in Generalized Pustular Psoriasis Area and Severity Index(GPPAS) total score at week 1 and week 4. If lower than the baseline score, indicate a certain degree of disease relief; conversely, if higher, it indicates an aggravation of the disease symptoms.'}, {'measure': 'Percentage of patients with Generalized Pustular Psoriasis Area and Severity Index(GPPASI) 50', 'timeFrame': '1 week and 4 weeks', 'description': 'Percentage of patients who achieved Generalized Pustular Psoriasis Area and Severity Index(GPPASI) 50 at week 1 and week 4.'}, {'measure': 'Percentage of patients with Generalized Pustular Psoriasis Area and Severity Index(GPPASI) 75', 'timeFrame': '1 week and 4 weeks', 'description': 'Percentage of patients who achieved Generalized Pustular Psoriasis Area and Severity Index(GPPASI) 75 at week 1 and week 4'}, {'measure': 'Percentage of patients with pustule subterm achieving a score of 0', 'timeFrame': '4 weeks', 'description': 'Percentage of patients with Generalized Pustular Psoriasis Physician Global Assessment(GPPGA) pustule subterm achieving a score of 0 (no visible pustules) at week 4.'}, {'measure': 'Change from baseline in Psoriasis Symptom Scale (PSS) score', 'timeFrame': '4 weeks', 'description': 'Change from baseline in Psoriasis Symptom Scale (PSS) score at week 4'}, {'measure': 'Change from baseline in disease life quality index (DLQI)', 'timeFrame': '4 weeks', 'description': 'Change from baseline in skin disease life quality index (DLQI) at week 4. If lower than the baseline score, indicate a certain degree of disease relief; conversely, if higher, it indicates an aggravation of the disease symptoms.'}, {'measure': 'Adverse Drug Event (AE)', 'timeFrame': '113 days or 169 days', 'description': 'Any untoward medical occurrence of a subject following drug treatment or exposure to an experimental factor, whether or not causally related to treatment or exposure.'}, {'measure': 'Serious Adverse Event (SAE)', 'timeFrame': '113 days or 169 days', 'description': 'An event that occurs in the course of a clinical trial that results in the death of a subject or patient, serious deterioration in health, hospitalization or prolongation of hospitalization, permanent disability or loss of function, or serious consequences such as birth defects or birth defects.'}, {'measure': 'Treatment-Emergent Adverse Events (TEAES)', 'timeFrame': '113 days or 169 days', 'description': 'Adverse events that occur during treatment, including from the start of treatment to a certain period of time after the end of treatment, may be directly or indirectly related to treatment.'}, {'measure': 'Abnormal clinical laboratory examination indicators', 'timeFrame': '113 days or 169 days', 'description': 'Any laboratory abnormalities that occur during the test.'}, {'measure': 'Time of maximum concentration (Tmax)', 'timeFrame': '1 hour pre-dose on day 1, immediately post dose, 1, 6, 24, 48, 168, 336, 504, 672, 1344, 2016, 2688 hours post dose. Day 8 Immediately after the end of salvage therapy administration, 1, 6, 24, 48 hours post dose', 'description': 'It refers to the time it takes for the human blood concentration curve to reach the highest concentration (peak concentration) after a single dose, measured in hours or minutes.'}, {'measure': 'Maximum Concentration (Cmax)', 'timeFrame': '1 hour pre-dose on day 1, immediately post dose, 1, 6, 24, 48, 168, 336, 504, 672, 1344, 2016, 2688 hours post dose. Day 8 Immediately after the end of salvage therapy administration, 1, 6, 24, 48 hours post dose', 'description': 'The highest blood concentration reached after the drug is absorbed in the body.'}, {'measure': 'Area Under the Curve (AUC)', 'timeFrame': '1 hour pre-dose on day 1, immediately post dose, 1, 6, 24, 48, 168, 336, 504, 672, 1344, 2016, 2688 hours post dose. Day 8 Immediately after the end of salvage therapy administration, 1, 6, 24, 48 hours post dose', 'description': 'It refers to the area covered by the concentration of a drug in the blood under the curve of changes over time.'}, {'measure': 'Apparent Volume of Distribution(Vd/F)', 'timeFrame': '1 hour pre-dose on day 1, immediately post dose, 1, 6, 24, 48, 168, 336, 504, 672, 1344, 2016, 2688 hours post dose. Day 8 Immediately after the end of salvage therapy administration, 1, 6, 24, 48 hours post dose', 'description': 'When the drug reaches dynamic equilibrium in the body, the ratio of the amount of drug in the body to the blood concentration is called the apparent volume of distribution.'}, {'measure': 'Apparent Clearance (CL/F)', 'timeFrame': '1 hour pre-dose on day 1, immediately post dose, 1, 6, 24, 48, 168, 336, 504, 672, 1344, 2016, 2688 hours post dose. Day 8 Immediately after the end of salvage therapy administration, 1, 6, 24, 48 hours post dose', 'description': 'The sum of drug clearance rates of liver and kidney, etc.'}, {'measure': 'Plasma half-life time (t1/2)', 'timeFrame': '1 hour pre-dose on day 1, immediately post dose, 1, 6, 24, 48, 168, 336, 504, 672, 1344, 2016, 2688 hours post dose. Day 8 Immediately after the end of salvage therapy administration, 1, 6, 24, 48 hours post dose', 'description': 'The time it takes for the concentration of the drug in the plasma to drop by half.'}, {'measure': 'Anti-drug antibody (ADA)', 'timeFrame': 'Through study completion, an average of half a year', 'description': 'Incidence of anti-drug antibodies (ADA) in subjects.'}]}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Generalized Pustular Psoriasis']}, 'descriptionModule': {'briefSummary': 'This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study, all subjects need to use TQH2929 injection/placebo. The aim was to demonstrate the efficacy and safety of TQH2929 injection in patients with acute exacerbations of generalized pustular psoriasis, with a total of 36 subjects.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Age ≥ 18 or ≤75 years old at screening, regardless of gender;\n* Meet the diagnostic criteria defined by the 2017 European Society for Clinical Nutrition and Metabolism (ESPEN) Research Workshop (ERASPEN) consensus and be diagnosed as （generalized pustular psoriasis(GPP);\n* Compliant with GPP acute onset;\n* Able to read and understand, and willing to sign the informed consent form;\n* Willing and compliant with study visits and related procedures;\n* Female subjects of childbearing age should agree that contraceptive measures must be used during the study and for 6 months after the end of the study;\n\nExclusion Criteria:\n\n* Pustules are limited to psoriasis vulgaris on psoriasis plaques;\n* Concomitant skin disease or medical disease that may interfere with the investigator's evaluation of the subject's treatment response;\n* Presence of severe, progressive, or uncontrolled disease, or signs and symptoms that are not suitable for participation in the investigator, in the judgment of the investigator:\n* Serum virological abnormalities during the screening period;\n* Chest radiology examination shows that the subject has active tuberculosis or a history of contact with open tuberculosis subjects in the past 6 months or a positive Interferon-Gamma Release Assays(IGRA) test;\n* History of serious infection leading to hospitalization within 2 months prior to baseline;\n* Active infection requiring systemic antibiotics, systemic antifungals, or systemic antiviral therapy within 2 weeks prior to baseline, according to the investigator's assessment;\n* History of opportunistic infection within 6 months prior to baseline;\n* Received live (attenuated) vaccine treatment within 12 weeks prior to baseline;\n* Any major surgery within 4 weeks prior to baseline or planned major surgery during the study;\n* Received blood transfusion within 4 weeks prior to baseline;\n* Participated in clinical trials of other drugs or medical devices within 4 weeks before baseline;\n* Any known or suspected congenital or acquired immunodeficiency state or condition that may compromise the subject's immune status;\n* Subjects with any type of active malignancy or a history of malignancy;\n* Alcohol, drug and known drug dependence;\n* Pregnant or lactating women;\n* Subjects cannot tolerate intravenous infusion administration."}, 'identificationModule': {'nctId': 'NCT07314060', 'briefTitle': 'A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis', 'organization': {'class': 'INDUSTRY', 'fullName': 'Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'}, 'officialTitle': 'A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of TQH2929 Injection in Patients With Acute Exacerbations of Generalized Pustular Psoriasis', 'orgStudyIdInfo': {'id': 'TQH2929-II-01'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'TQH2929 Injections', 'description': 'Intravenous infusion, single dose', 'interventionNames': ['Drug: TQH2929 Injections']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'TQH2929 Placebo', 'description': 'Intravenous infusion, single dose', 'interventionNames': ['Drug: TQH2929 Placebo']}], 'interventions': [{'name': 'TQH2929 Injections', 'type': 'DRUG', 'description': 'TQH2929 is a humanized monoclonal antibody that interfering with the signal cascade.', 'armGroupLabels': ['TQH2929 Injections']}, {'name': 'TQH2929 Placebo', 'type': 'DRUG', 'description': 'Placebo contains no active substance.', 'armGroupLabels': ['TQH2929 Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '100034', 'city': 'Beijing', 'state': 'Beijing Municipality', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Hang Li, Doctor', 'role': 'CONTACT', 'email': 'drlihang@126.com', 'phone': '13693058190'}], 'facility': 'Peking University First Hospita', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'zip': '100191', 'city': 'Beijing', 'state': 'Beijing Municipality', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Wenhui Wang, Doctor', 'role': 'CONTACT', 'email': 'wwh0608@126.com', 'phone': '156 1190 8751'}], 'facility': 'Peking University Third Hospital', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'zip': '350000', 'city': 'Fuzhou', 'state': 'Fujian', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Niu Xiang, Master', 'role': 'CONTACT', 'email': '408089668@qq.com', 'phone': '13696834928'}], 'facility': 'The First Affiliated Hospital of Fujian Medical University', 'geoPoint': {'lat': 26.06139, 'lon': 119.30611}}, {'zip': '510091', 'city': 'Guangzhou', 'state': 'Guangdong', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Bin Yang, Doctor', 'role': 'CONTACT', 'email': 'yangbin101@hotmail.com', 'phone': '13922207231'}], 'facility': 'Southern Medical University Dermatology Hospital', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'zip': '510120', 'city': 'Guangzhou', 'state': 'Guangdong', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Zhenrui Shi, Doctor', 'role': 'CONTACT', 'email': '839241987@qq.com', 'phone': '13908008569'}], 'facility': 'Sun Yat-sen Memorial Hospital, Sun Yat-sen University', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'zip': '550004', 'city': 'Guiyang', 'state': 'Guizhou', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Yu Wang, Doctor', 'role': 'CONTACT', 'email': '84343798@qq.com', 'phone': '13984171241'}], 'facility': 'The Affiliated Hospital of Guizhou Medical University', 'geoPoint': {'lat': 26.58333, 'lon': 106.71667}}, {'zip': '050000', 'city': 'Shijiazhuang', 'state': 'Hebei', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Yanling Li, Master', 'role': 'CONTACT', 'email': 'lyldoctor@sina.com', 'phone': '15130119920'}], 'facility': 'The Second Hospital Of Hebei Medical University', 'geoPoint': {'lat': 38.04139, 'lon': 114.47861}}, {'zip': '471000', 'city': 'Luoyang', 'state': 'Henan', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Bin Zhang, Bachelor', 'role': 'CONTACT', 'email': '1079378529@qq.com', 'phone': '18637968669'}], 'facility': 'The Second Affiliated Hospital of Henan University of science and technology', 'geoPoint': {'lat': 34.67345, 'lon': 112.43684}}, {'zip': '450000', 'city': 'Zhengzhou', 'state': 'Henan', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Yuhong Zhang, Master', 'role': 'CONTACT', 'email': 'zyhdyxiang@126.com', 'phone': '15837180902'}], 'facility': 'Zhengzhou Central Hospital', 'geoPoint': {'lat': 34.75778, 'lon': 113.64861}}, {'zip': '450003', 'city': 'Zhengzhou', 'state': 'Henan', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Hongwei Liu, Bachelor', 'role': 'CONTACT', 'email': '1831824589@qq.com', 'phone': '18637110289'}], 'facility': "Henan Provincial People's Hospital", 'geoPoint': {'lat': 34.75778, 'lon': 113.64861}}, {'zip': '450052', 'city': 'Zhengzhou', 'state': 'Henan', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Hongwei Cao, Master', 'role': 'CONTACT', 'email': 'zdwfy2223chw@163.com', 'phone': '13598867509'}], 'facility': 'The fifth Affiliated hospital of zhengzhou university', 'geoPoint': {'lat': 34.75778, 'lon': 113.64861}}, {'zip': '442000', 'city': 'Shiyan', 'state': 'Hubei', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Zudong Meng, Master', 'role': 'CONTACT', 'email': '1970547910@qq.com', 'phone': '13997837543'}], 'facility': 'Shiyan Renmin Hospital', 'geoPoint': {'lat': 32.6475, 'lon': 110.77806}}, {'zip': '430060', 'city': 'Wuhan', 'state': 'Hubei', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Shan Jiang, Doctor', 'role': 'CONTACT', 'email': 'Jiangshan794101@126.com', 'phone': '13659892065'}], 'facility': 'Renmin Hospital of Wuhan University', 'geoPoint': {'lat': 30.58333, 'lon': 114.26667}}, {'zip': '410007', 'city': 'Changsha', 'state': 'Hunan', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Jianyuan Xi, Doctor', 'role': 'CONTACT', 'email': 'xijianyuan2010@126.com', 'phone': '15974172722'}], 'facility': 'The First Hospital of Hunan University of Chinese Medicine', 'geoPoint': {'lat': 28.19874, 'lon': 112.97087}}, {'zip': '410008', 'city': 'Changsha', 'state': 'Hunan', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Juan Su, Doctor', 'role': 'CONTACT', 'email': '3694944834@qq.com', 'phone': '15116408921'}], 'facility': 'Xiangya Hospital of Central South University', 'geoPoint': {'lat': 28.19874, 'lon': 112.97087}}, {'zip': '41800', 'city': 'Huaihua', 'state': 'Hunan', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Xuelian Zheng, Master', 'role': 'CONTACT', 'email': '3466098939@qq.com', 'phone': '13307459875'}], 'facility': 'The General Hospital Of Hunan University Of Medicine', 'geoPoint': {'lat': 27.56337, 'lon': 110.00404}}, {'zip': '130012', 'city': 'Changchun', 'state': 'Jilin', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Shanshan Li, Doctor', 'role': 'CONTACT', 'email': 'shansalee@163.com', 'phone': '13756661632'}], 'facility': 'The first hospital of jilin university', 'geoPoint': {'lat': 43.88, 'lon': 125.32278}}, {'zip': '110001', 'city': 'Shenyang', 'state': 'Liaoning', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Xinghua Gao, Doctor', 'role': 'CONTACT', 'email': 'gaobarry@hotmail.com', 'phone': '13940152467'}], 'facility': 'The first hospital of china medical university', 'geoPoint': {'lat': 41.79222, 'lon': 123.43278}}, {'zip': '250022', 'city': 'Jinan', 'state': 'Shandong', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Furen Zhang, Doctor', 'role': 'CONTACT', 'email': 'zhangfurenlcsy@163.com', 'phone': '13608921718'}], 'facility': 'Shandong First Medical University Affiliated Dermatology Hospital', 'geoPoint': {'lat': 36.66833, 'lon': 116.99722}}, {'zip': '200443', 'city': 'Shanghai', 'state': 'Shanghai Municipality', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Yangfeng Ding, Doctor', 'role': 'CONTACT', 'email': 'dingyangfeng@aliyun.com', 'phone': '18017336636'}], 'facility': 'Shanghai Skin Disease Hospital', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'zip': '710061', 'city': 'Xi’an', 'state': 'Shanxi', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Songmei Geng, Doctor', 'role': 'CONTACT', 'email': 'gsm312@yahoo.com', 'phone': '13060423612'}], 'facility': "The Second Affiliated Hospital of Xi'an Jiaotong University", 'geoPoint': {'lat': 35.99785, 'lon': 113.52486}}, {'zip': '610000', 'city': 'Chengdu', 'state': 'Sichuan', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Yanyan Feng, Doctor', 'role': 'CONTACT', 'email': 'Yolanda20220918@163.com', 'phone': '19150169967'}], 'facility': "Chengdu Second People's Hospital", 'geoPoint': {'lat': 30.66667, 'lon': 104.06667}}, {'zip': '610000', 'city': 'Chengdu', 'state': 'Sichuan', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Lixia Zhang, Doctor', 'role': 'CONTACT', 'email': 'zhanglixia0310@163.com', 'phone': '17708130396'}], 'facility': "Sichuan Provincial People' s Hospital", 'geoPoint': {'lat': 30.66667, 'lon': 104.06667}}, {'zip': '646000', 'city': 'Luzhou', 'state': 'Sichuan', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Chengsong He, Master', 'role': 'CONTACT', 'email': '13700980878@163.com', 'phone': '13700980878'}], 'facility': 'The Affiliated Hospital of Southwest Medical University', 'geoPoint': {'lat': 28.8903, 'lon': 105.42575}}, {'zip': '646000', 'city': 'Luzhou', 'state': 'Sichuan', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Qing Peng, Doctor', 'role': 'CONTACT', 'email': 'qingpeng9712118@163.com', 'phone': '18181873310'}], 'facility': 'The Affiliated Hospital of Southwest Medical University', 'geoPoint': {'lat': 28.8903, 'lon': 105.42575}}, {'zip': '300052', 'city': 'Tianjin', 'state': 'Tianjin Municipality', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Huiping Wang, Doctor', 'role': 'CONTACT', 'email': 'huiping1208@163.com', 'phone': '13702031042'}], 'facility': 'Tianjin Medical University General Hospital', 'geoPoint': {'lat': 39.14222, 'lon': 117.17667}}, {'zip': '300120', 'city': 'Tianjin', 'state': 'Tianjin Municipality', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Litao Zhang, Doctor', 'role': 'CONTACT', 'email': 'ZhanglitaoYG@163.co', 'phone': '18602228122'}], 'facility': 'Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital', 'geoPoint': {'lat': 39.14222, 'lon': 117.17667}}, {'zip': '830001', 'city': 'Ürümqi', 'state': 'Xinjiang', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Xiaojing Kang, Doctor', 'role': 'CONTACT', 'email': 'drkangxj666@163.com', 'phone': '13999927999'}], 'facility': "People's Hospital of Xinjiang Uygur Autonomous Region", 'geoPoint': {'lat': 43.80096, 'lon': 87.60046}}, {'zip': '830013', 'city': 'Ürümqi', 'state': 'Xinjiang', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Xuefeng Wan, Doctor', 'role': 'CONTACT', 'email': 'xjwanxuefeng@sina.com', 'phone': '13579867192'}], 'facility': 'The First Affiliated Hospital of Xinjiang Medical University', 'geoPoint': {'lat': 43.80096, 'lon': 87.60046}}, {'zip': '650032', 'city': 'Kunming', 'state': 'Yunnan', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Ying Tu, Doctor', 'role': 'CONTACT', 'email': '747307239@qq.com', 'phone': '13608711764'}], 'facility': 'The First Affiliated Hospital of Kunming Medical University', 'geoPoint': {'lat': 25.03889, 'lon': 102.71833}}, {'zip': '314001', 'city': 'Jiaxing', 'state': 'Zhejiang', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Wuhao Yin, Master', 'role': 'CONTACT', 'email': 'whyin69@sina.com', 'phone': '13957323606'}], 'facility': 'Jiaxing First Hospital', 'geoPoint': {'lat': 30.7522, 'lon': 120.75}}, {'zip': '315020', 'city': 'Ningbo', 'state': 'Zhejiang', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Bingjiang Lin, Master', 'role': 'CONTACT', 'email': 'linbingj@163.com', 'phone': '17757461212'}], 'facility': 'The first affiliated hospital of ningbo university', 'geoPoint': {'lat': 29.87819, 'lon': 121.54945}}], 'centralContacts': [{'name': 'Hang Li, Doctor', 'role': 'CONTACT', 'email': 'drlihang@126.com', 'phone': '13693058190'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Chia Tai Tianqing Pharmaceutical Group Co., Ltd.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}